The second Society of Nuclear Medicine and Molecular Imaging (SNMMI) AI Summit, organized by the SNMMI AI Task Force, took ...

Radiopharmaceuticals represent a promising new frontier in cancer therapy. In the United States, cancer is the second leading cause of death. There is an urgent need to develop new therapies to meet ...

Recently, a collaborative effort among research centers in the United States and Europe resulted in the development of ...

Incidental findings from PET are common, induce unnecessary patient anxiety, and incur substantial costs to the health care system, with further diagnostic clarification potentially delaying important ...

In recent years, the tumor microenvironment has gained interest as a therapeutic target in the treatment of cancer. The tumor microenvironment can comprise a substantial part of the tumor: in ...

Increased expression of fibroblast-activating protein (FAP) in fibrous caps may contribute to progression of atherosclerotic plaques. Methods: Forty-one patients who underwent 68Ga-conjugated ...

Journal of Nuclear Medicine April 2025, jnumed.124.269132; DOI: https://doi.org/10.2967/jnumed.124.269132 ...

We took a novel approach to testing between the competing models of Aβ accumulation: we used the whole-cortex Aβ profile derived from the longitudinal study of Jack et al. (in which the patients did ...

Fibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP ...

A compendium of about 100 radiopharmaceuticals, based on the OLINDA/EXM version 2.0 software, is presented. A new generation of voxel-based, realistic human computational phantoms developed by the ...

The PSMA-targeting ligand 177 Lu-PSMA-617 was prepared in compliance with good manufacturing practices. Radio–high-performance liquid chromatography as the primary method of quality control was ...

RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...